Citigroup Downgrades Reata Pharmaceuticals (NASDAQ:RETA) to Neutral

Citigroup cut shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) from a buy rating to a neutral rating in a research report released on Tuesday morning, Marketbeat reports. Citigroup currently has $172.50 target price on the stock, up from their prior target price of $127.00. Other equities analysts have also recently issued reports about the […]

Related Keywords

China ,Arizona ,United States ,Leerink Partnrs ,Stifel Nicolaus ,Michaeld Wortley ,Bhaskar Anand ,Reata Pharmaceuticals Company Profile ,Belpointe Asset Management ,Analyst Recommendations For Reata Pharmaceuticals ,China Universal Asset Management Co ,Pricet Rowe Associates Inc ,Reata Pharmaceuticals Trading Down ,News Ratings For Reata Pharmaceuticals Daily ,Hedge Funds Weigh In On Reata Pharmaceuticals ,Cantor Fitzgerald ,Reata Pharmaceuticals ,Reata Pharmaceuticals Inc ,Citigroup ,Mirae Asset Global Investments Co ,Free Report ,Pharmaceuticals Trading Down ,Get Free Report ,Universal Asset Management ,Asset Global Investments ,Asset Management ,State Retirement System ,Pricet Rowe Associates ,Reata Pharmaceuticals Daily ,Nasdaq Reta ,Greta ,Medical ,Downgrade ,Citigroup Inc ,